Point of View 03.15.19 Share on Twitter Share on Facebook Share on LinkedIn Carl June, MD: How He Developed CAR-T and Reflections on Cell Therapy Interviewed by Lily Oncology’s Kim Blackwell, MD, Parker Institute director Carl June, MD, recalls breakthrough moments in his career that led to discovering how to engineer a T-cell that can target and destroy cancer, now known as CAR-T therapy and manufactured on the market under the name Kymriah. He gives a nod to his oncology training in the navy and his work in infectious disease as major and unplanned contributors to his success. They also look forward into the future and identify other exciting areas he sees in the field of cell therapy. This talk was recorded at the Precision Medicine World Conference in January 2019 in Silicon Valley. Related Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer
Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy
Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn
Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer